Business Wire

Mavenir Announces R & D Center of Excellence Focused on Artificial Intelligence/Machine Learning Signaling Security

Del

Mavenir, the leader in accelerating and redefining network transformation for Service Providers, has today announced its R&D centre of excellence in Brno, Czech Republic focused on Artificial Intelligence/machine learning signaling security solutions. Mavenir’s solution provides the most advanced signaling monitoring, active filtering and powerful analytics to ensure networks remain fully functional and operational, while ensuring customers stay protected when using network services.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170608005425/en/

Network Security (Graphic: Business Wire)

Network Security (Graphic: Business Wire)

Although Signaling System 7 (SS7) has been widely used for decades, hackers only began exploiting vulnerabilities in recent years and operators are now ramping up the signaling security in their networks. This extended security focus comes as an operator in Germany confirmed that some of its customers had their bank accounts drained last month, through SS7 signaling fraud.

Mavenir has deep expertise in signaling security capabilities, with Security Gateways (SeGWs) and Diameter Edge Agents (DEAs), Signaling Transfer Points (STPs) and Diameter Routing Agents (DRAs) to ensure the most advanced edge and core network signaling protection available.

Mavenir also provides security auditing services. Results of a recent SS7 audit of more than thirty networks indicated that every network has some vulnerability in SS7. The exploits observed during auditing enable attacks that range from call and message eavesdropping to denial of service and fraud.

“Operators are seeking to mitigate against network attacks and vulnerabilities, in addition to accelerating their efforts to implement firewall solutions for the next generation of networks,” said Pardeep Kohli, President and CEO at Mavenir. “Our network security solution uses Artificial Intelligence/machine learning and analytics for SS7 Security, Diameter Security, SIP Security, and Network Optimization.”

Kohli continued, “Legacy SS7 technology may eventually be replaced by Diameter or SIP, but SS7 will be around for some time and therefore must be secured. Continuing to address security flaws in signaling protocols with an optimal, multi-layer solution means that operators can shield enterprises and subscribers while ensuring their services remain fully available and generating revenue.”

Mavenir’s network security solutions are deployed in multiple operator networks across North America, EMEA and APAC regions. Artificial intelligence and machine learning power Mavenir’s world leading messaging SIM-box, grey-route and fraud detection capability offered by our SpamShield product.

Want to learn more? Mavenir will be exhibiting (Booth 5G565) and speaking at Network Security and 5G World in Jun 13-15th in London.

About Mavenir Systems, Inc. | Mavenir

Mavenir is the leader in accelerating and redefining network transformation for Service Providers, by offering a comprehensive product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.

Through its industry first VoLTE, VoWiFi, Advanced Messaging (RCS), Multi ID, Visual Voicemail and Cloud RAN solutions, and serving 350+ CSPs across 3.5 billion subscribers, Mavenir’s platform enables Service Providers to successfully deliver next generation vision today and realize new revenue streams and operational efficiencies. www.mavenir.com.

Contact information

Media:
Matter for Mavenir
Nicole Brooks, 971-246-7898
mavenir@matternow.com
or
Hotwire PR
Hannah Lock / Dom Conolly
mavenir@hotwirepr.com
+44 (0) 207 608 2500

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom